Caris Life Sciences, Inc.

NasdaqGS:CAI Stock Report

Market Cap: US$5.2b

Caris Life Sciences Management

Management criteria checks 2/4

Caris Life Sciences' CEO is David Halbert, appointed in Jan 2008, has a tenure of 18.5 years. total yearly compensation is $20.35M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 43.37% of the company’s shares, worth $2.24B. The average tenure of the management team and the board of directors is 8.5 years and 13.5 years respectively.

Key information

David Halbert

Chief executive officer

US$20.4m

Total compensation

CEO salary percentage3.76%
CEO tenure18.5yrs
CEO ownership43.4%
Management average tenure8.5yrs
Board average tenure13.5yrs

Recent management updates

Recent updates

Narrative Update • Jun 26

CAI: Strong Q1 Execution And Buyback Will Support Future Upside

Analysts have revised their price target on Caris Life Sciences to $21.00 from $26.23, citing updated assumptions that combine lower projected revenue growth with slightly higher expected profit margins and a reduced future P/E multiple. What’s in the News for Caris Life Sciences Caris Life Sciences reported Q1 2026 results with revenue rising 79%, molecular profiling revenue rising 85%, gross margin expansion, and positive Adjusted EBITDA and free cash flow, as the company positions itself as an AI-enabled precision oncology and molecular diagnostics platform (source: recent earnings coverage).
Seeking Alpha • Apr 13

Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity

Summary Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and Caris Assure. These contributed to CAI’s strong 2025 revenue growth. CAI clearly benefited from higher reimbursements, better pricing, and rising test volumes in 2025. Similarly, its pipeline adds optionality with the Caris Detect, MI Clarity, and MRD programs for multi-cancer detection and breast recurrence risk. In my view, CAI’s current valuation multiples seem compelling after its post-IPO pullback. As such, I deem CAI a good long-term “Buy” in oncology diagnositcs. Read the full article on Seeking Alpha
New Narrative • Feb 18

Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future

Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?
Analysis Article • Feb 05

Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon

There wouldn't be many who think Caris Life Sciences, Inc.'s ( NASDAQ:CAI ) price-to-sales (or "P/S") ratio of 9.5x is...

CEO Compensation Analysis

How has David Halbert's remuneration changed compared to Caris Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$411m

Dec 31 2025US$20mUS$765k

-US$538m

Sep 30 2025n/an/a

-US$682m

Jun 30 2025n/an/a

-US$799m

Mar 31 2025n/an/a

-US$371m

Dec 31 2024US$2mUS$750k

-US$378m

Compensation vs Market: David's total compensation ($USD20.35M) is above average for companies of similar size in the US market ($USD8.35M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Halbert (70 yo)

18.5yrs
Tenure
US$20,350,571
Compensation

Dr. David Dean Halbert, M.D., DSc (h.c.) Founded Caris, Ltd. in 2005 and serves as its General Partner. Dr. Halbert serves as the Chairman, Founder and Chief Executive Officer at U.S.Caris MPI, Inc. (d/b/...

Leadership Team

NamePositionTenureCompensationOwnership
David Halbert
Chairman18.5yrsUS$20.35m43.37%
$ 2.2b
Brian Brille
Executive Vice Chairman & Executive VP8.5yrsno data0.19%
$ 10.0m
David Spetzler
President9.7yrsUS$11.58m0.19%
$ 9.7m
J. Denton
Senior VP3.8yrsUS$5.35m0.018%
$ 956.0k
Luke Power
Senior VP9.3yrsno data0.0054%
$ 280.4k
Jon Harmon
Senior VP & Chief Operations Officer3.5yrsno datano data
Valeriy Domenyuk
Senior VP & CTOno datano datano data
Milan Radovich
Senior VP & Chief Scientific Officer3.5yrsno datano data
Narendra Chokshi
Senior Vice President of Corporate Developmentno datano datano data
Jeremy O'Brien
Senior Vice President of Human Resourcesno datano datano data
Stephanie Thomas
Executive VP & Chief of Staff at Office of the CEOno datano datano data
Jim Abraham
Senior VP & Chief Innovation Officerno datano datano data
8.5yrs
Average Tenure
49yo
Average Age

Experienced Management: CAI's management team is seasoned and experienced (8.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Halbert
Chairman14.8yrsUS$20.35m43.37%
$ 2.2b
Brian Brille
Executive Vice Chairman & Executive VP8.5yrsno data0.19%
$ 10.0m
Peter Castleman
Lead Independent Director18.5yrsUS$647.34k3.67%
$ 189.9m
Jon Halbert
Director12.2yrsUS$350.00k0.48%
$ 24.8m
Laurie Johansen
Independent Director18.5yrsUS$359.00k0.11%
$ 5.8m
George Demetri
Member of Scientific Advisory Boardno datano datano data
Donald Berry
Member of Scientific Advisory Boardno datano datano data
Clay Marsh
Member of Scientific Advisory Boardno datano datano data
Danny Phillips
Independent Director10.9yrsUS$412.06k0%
$ 0
Anna Barker
Member of Scientific Advisory Boardno datano datano data
Thomas Herzog
Member of Scientific Advisory Boardno datano datano data
Amy Heimberger
Member of Scientific Advisory Boardno datano datano data
13.5yrs
Average Tenure
66yo
Average Age

Experienced Board: CAI's board of directors are seasoned and experienced ( 13.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 19:03
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Caris Life Sciences, Inc. is covered by 14 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Michael RyskinBofA Global Research
Mark MassaroBTIG